AstraZeneca PLC (LON:AZN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of £112.23 ($143.41) and traded as high as £115.52 ($147.61). AstraZeneca shares last traded at £113.92 ($145.57), with a volume of 1,971,750 shares.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. restated an "overweight" rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research note on Friday, March 7th. Finally, Berenberg Bank reiterated a "buy" rating and set a GBX 140 ($1.79) price target on shares of AstraZeneca in a research report on Wednesday, March 26th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of GBX 7,542.80 ($96.38).
Get Our Latest Report on AstraZeneca
AstraZeneca Trading Up 2.8 %
The firm's 50-day simple moving average is £115.54 and its 200 day simple moving average is £111.70. The stock has a market cap of £198.82 billion, a P/E ratio of 28.32, a PEG ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
